May. 20 at 5:28 PM
$BHVN OLE Comparison: When looking at the long-term data for actual epilepsy patients taking these treatments every single day, the contrast in tolerability becomes even clearer:Xenon’s OLE Data: In Xenon's long-term OLE analysis (from their X-TOLE studies), the side effects are persistent. Over 21.8% of patients reported dizziness, 15.3% reported headaches, 12.7% suffered from somnolence, and 12.7% experienced accidental falls due to coordination issues. Additionally, 20.7% of patients had to reduce their daily dose just to handle these side effects. Biohaven’s OLE Data: In Biohaven's interim OLE updates, the company reported no severe CNS adverse events and a uniquely low incidence of overall dizziness or drowsiness. Patient dropouts and dose reductions due to tolerability issues have remained remarkably low.
